Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Healthcare Triangle (HCTI) Research & Development (2020 - 2025)

Healthcare Triangle's Research & Development history spans 6 years, with the latest figure at $279000.0 for Q4 2025.

  • On a quarterly basis, Research & Development rose 448.75% to $279000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $537000.0, a 25.17% increase, with the full-year FY2025 number at $536000.0, up 24.94% from a year prior.
  • Research & Development hit $279000.0 in Q4 2025 for Healthcare Triangle, up from $59000.0 in the prior quarter.
  • Over the last five years, Research & Development for HCTI hit a ceiling of $5.0 million in Q4 2022 and a floor of -$80000.0 in Q4 2024.
  • Historically, Research & Development has averaged $757950.0 across 5 years, with a median of $243000.0 in 2024.
  • Biggest five-year swings in Research & Development: crashed 176.92% in 2024 and later soared 448.75% in 2025.
  • Tracing HCTI's Research & Development over 5 years: stood at $1.5 million in 2021, then surged by 234.35% to $5.0 million in 2022, then plummeted by 97.9% to $104000.0 in 2023, then crashed by 176.92% to -$80000.0 in 2024, then soared by 448.75% to $279000.0 in 2025.
  • Business Quant data shows Research & Development for HCTI at $279000.0 in Q4 2025, $59000.0 in Q3 2025, and $55000.0 in Q2 2025.